Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The companys products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracytes common stock is listed on The NASDAQ Global Market under the symbol VCYT.
Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual Meeting
Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017
All Press Releases